Xin Lang Zheng Quan·2025-10-31 04:29Core Insights - Xinhua Pharmaceutical, established in 1998 and listed in 1997, is a significant player in the raw material pharmaceutical industry in China, particularly in the field of analgesics, with a full industry chain advantage [1] Group 1: Business Performance - In Q3 2025, Xinhua Pharmaceutical reported a revenue of 6.763 billion, ranking third among 47 companies in the industry, with the top competitor, Puluo Pharmaceutical, generating 7.764 billion [2] - The net profit for the same period was 267 million, placing Xinhua ninth in the industry, while the leading company, Zhejiang Pharmaceutical, achieved a net profit of 867 million [2] Group 2: Financial Ratios - As of Q3 2025, Xinhua Pharmaceutical's debt-to-asset ratio was 40.72%, down from 42.25% year-on-year, which is higher than the industry average of 27.75% [3] - The gross profit margin for Q3 2025 was 19.17%, a decrease from 23.50% year-on-year, and below the industry average of 35.38% [3] Group 3: Executive Compensation - The chairman, He Tongqing, received a salary of 1.8981 million in 2024, an increase of 285,300 from 2023 [4] - The general manager, Xu Wenhui, earned 1.8081 million in 2024, up by 286,700 from the previous year [4] Group 4: Shareholder Information - As of June 30, 2025, the number of A-share shareholders decreased by 2.48% to 76,500, while the average number of shares held per shareholder increased by 10.89% to 6,442.22 [5] - By September 30, 2025, major shareholders included Hong Kong Central Clearing Limited and various ETFs, with notable decreases in their holdings [5]